Francesca Sacchi

Francesca Sacchi

Auto-generated profile, based on publicly available information

Francesca Sacchi

Department of Medical and Surgical Sciences (DIMEC), University of Bologna

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
NPNicola Pianca
Nicola Pianca
FSFrancesca Sacchi
Francesca Sacchi
KUKfir Baruch Umansky
Kfir Baruch Umansky
MCMaila Chirivì
Maila Chirivì
LILuisa Iommarini
Luisa Iommarini
Gabriele D'UvaGabriele D'Uva
Gabriele D'Uva

22 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CMCarmen Miano
Carmen Miano
AMAlessandra Morselli
Alessandra Morselli
FPfrancesca pontis
francesca pontis
CBChiara Bongiovanni
Chiara Bongiovanni
FSFrancesca Sacchi
Francesca Sacchi
Gabriele D'UvaGabriele D'Uva
Gabriele D'Uva
ERBB3, also known as HER3, is a tyrosine kinase transmembrane receptor of the ERBB family. Upon binding to neuregulin 1 (NRG1), ERBB3 preferentially dimerizes with HER2 (ERBB2), in turn inducing aggressive features in several cancer types. The analysis of a dataset of breast cancer patients unveiled that higher ERBB3 mRNA expression correlates with shorter relapse-free survival in basal-like breast cancers, despite low ERBB3 expression in this breast cancer subtype. Administration of neuregulin 1 beta (NRG1β) significantly affected neither cellular proliferation nor the basal migratory ability of basal-like/triple-negative quasi-normal MCF10A breast cells, cultured in mono-layer conditions. Furthermore, no significant regulation in cell morphology or in the expression of basal/myoepithelial and luminal markers was observed upon stimulation with NRG1β. In non-adherent conditions, NRG1β administration to MCF10A cells did not significantly influence cell survival; however, it robustly induced cell growth as spheroids (3D growth). Intriguingly, a remarkable upregulation of ERBB3 and ERBB2 protein abundance was observed in 3D compared to 2D cell cultures, and NRG1β-induced 3D cell growth was efficiently prevented by the anti-HER2 monoclonal antibody pertuzumab. Similar results were obtained by the analysis of basal-like/triple-negative breast cancer cellular models, MDA-MB-468 and MDA-MB-231 cells, in which NRG1β induced anchorage-independent cell growth that in turn was prevented or reduced by the simultaneous administration of anti-HER2 neutralizing antibodies. Finally, the ability of pertuzumab in suppressing NRG1β-induced 3D growth was also evaluated and confirmed in MCF10A engineered with HER2-overexpression. We suggest that the NRG1/ERBB3/ERBB2 pathway promotes the anchorage-independent growth of basal-like breast cancer cells. Importantly, we provide evidence that ERBB2 neutralization, in particular by pertuzumab, robustly inhibits this process. Our results pave the way towards the development of novel anticancer strategies for basal-like breast cancer patients based on the interception of the NRG1/ERBB3/ERBB2 signaling axis.

6 February 2026 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
SPSilvia Da Pra
Silvia Da Pra
SBStefano Boriati
Stefano Boriati
CMCarmen Miano
Carmen Miano
FSFrancesca Sacchi
Francesca Sacchi
CBChristopher Batho
Christopher Batho
Gabriele D'UvaGabriele D'Uva
Gabriele D'Uva

11 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
FSF. Sacchi
F. Sacchi
SBS. Boriati
S. Boriati
RCR. Caliandro
R. Caliandro
SPS. Da Pra
S. Da Pra
IBI. Del Bono
I. Del Bono
GDG. D’Uva
G. D’Uva
Endogenous corticosteroids bind both the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR), yet how this shared ligand input is decoded in the heart remains unclear. Previous work established that corticosterone suppresses postnatal cardiomyocyte proliferation through GR. Here we show that corticosteroid responses are governed by a functional GR-MR hierarchy and by cellular context. Genetic or pharmacological GR inhibition redirects corticosterone towards cardiomyocyte proliferation, and MR antagonism or silencing abolishes this effect. GR disruption also enhances aldosterone-induced proliferation in cardiomyocyte-enriched cultures, indicating that GR restrains MR output beyond ligand allocation. However, aldosterone fails to increase cardiomyocyte proliferation in mixed cultures and instead stimulates fibroblast proliferation and activation. By contrast, corticosterone combined with GR inhibition promotes cardiomyocyte proliferation without inducing stromal proliferation or profibrotic activation. Both treatments induce MR nuclear localisation in fibroblasts, showing that their divergent stromal effects arise despite comparable receptor nuclear engagement. Following myocardial infarction, circulating corticosterone increases and GR inhibition enhances cardiomyocyte MR nuclear localisation. In adult murine myocardium, corticosterone plus GR antagonism increases cardiomyocyte cell-cycle activity in an MR-dependent manner, with analogous responses observed in porcine and human myocardium. These findings identify hierarchical and context-dependent GR-MR signalling as a mechanism of corticosteroid decoding and a potential route to cardiac regeneration.